Parsons P, et al. - In women with recurrent cervical cancer, researchers assessed the toxicities seen following bevacizumab combination chemotherapy. Participants were women with recurrent and metastatic cervical cancer who were treated with salvage chemotherapy with or without bevacizumab between 2005 and 2015. In these patients, hypoalbuminemia and bevacizumab treatments are significant predictors of fistula formation. Compared to 15% of the chemotherapy cohort, 46% of the bevacizumab cohort stopped treatment secondary to severe toxicities.